211 related articles for article (PubMed ID: 30679824)
21. [Successful treatment of post-allogeneic hematopoietic transplant immune thrombocytopenia with eltrombopag].
Narita Y; Uchiyama T; Mizumoto C; Takeoka T; Tomo K; Tsuji M; Ohno T
Rinsho Ketsueki; 2018; 59(11):2418-2422. PubMed ID: 30531136
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
[TBL] [Abstract][Full Text] [Related]
23. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
24. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.
Yan F; Lu N; Gu Z; Huang W; Wang S; Gao X; Dou L; Li F; Wang L; Li M; Liu D; Gao C
Ann Hematol; 2022 Feb; 101(2):397-408. PubMed ID: 34735613
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag use in a patient with Wiskott-Aldrich syndrome.
Gabelli M; Marzollo A; Notarangelo LD; Basso G; Putti MC
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643468
[TBL] [Abstract][Full Text] [Related]
26. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
[TBL] [Abstract][Full Text] [Related]
27. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.
Frey N; Jang JH; Szer J; Illés Á; Kim HJ; Ram R; Chong BH; Rowe JM; Borisenkova E; Liesveld J; Winer ES; Cherfi A; Aslanis V; Ghaznawi F; Strickland S
Lancet Haematol; 2019 Mar; 6(3):e122-e131. PubMed ID: 30704923
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
[TBL] [Abstract][Full Text] [Related]
32. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
Gill H; Leung GM; Lopes D; Kwong YL
Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929
[No Abstract] [Full Text] [Related]
33. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag in thrombocytopenia.
Lawson A
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
[No Abstract] [Full Text] [Related]
38. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation.
Nampoothiri RV; Ho L; McEwan C; Pasic I; Lam W; Law AD; Michelis FV; Thyagu S; Kim DDH; Gerbitz A; Viswabandya A; Lipton JH; Mattsson J; Kumar R
Bone Marrow Transplant; 2021 Oct; 56(10):2471-2476. PubMed ID: 34108675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
